Journal for ImmunoTherapy of Cancer (Nov 2021)
358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2021)